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Factor VHI:C Concentrate Purified From Plasma Using Monoclonal Antibodies:
Human Studies
By D.B. Brettler, A.D. Forsberg, P.H. Levine, J. Petillo, K. Lamon, and J.L. Sullivan
Conventional clotting factor concentrates have, until
recently. been “of intermediate purity.” containing <1 % of
the coagulation factor, and >99% extraneous plasma pro-
teins such as fibrinogen, fibronectin. gamma globulins. and
traces of many others. We report here the results of a new
factor VIII concentrate that is purified from human plasma
using a mouse monoclonal antibody to factor Vlll:vWF in an
affinity chromatography system. The resultant concen-
trate has an activity of between 3.000 and 5.000 U/mg
protein before albumin is added as a stabilizer. Seven
patients with severe hemophilia A and no inhibitor who
were positive for antibody to human immunodeficiency
virus (HIV) have been treated solely with this concentrate
for over 24 months. Factor usage in these patients has
ranged from 6i1 U/kg/yr to 2,022 U/kg/yr. These
F ACTOR VIII DEFICIENCY (hemophilia A) has his-
torically been treated with a variety of human blood
products. Until the l960s, whole blood and then fresh frozen
plasma were used. In 1964, Pool et al discovered that factor
VIII could be partially purified by precipitation in the cold.’
Cryoprecipitate was subsequently adopted as the accepted
treatment of hemophilia A. Lyophilized factor VIII concen-
trate was introduced in the late 19605.2 It has been the
therapy of choice since the early 1 970s, enabling hemophil-
iacs to treat themselves in a home therapy setting and thus
allowing the patients to greatly normalize their life func-
tions.3 Factor VIII concentrate is made from large plasma
pools and has been associated in the past with transmission of
hepatitis B, non-A, non-B hepatitis (NANBH), delta hepati-
tis, parvovirus, and human immunodeficiency virus (HIV).2’4
Since 1984, viral inactivation processes such as heat treat-
ment during preparation ofconcentrates have become widely
available commercially. Currently all factor concentrate
used in the United States has undergone viral inactivation.
It has been postulated that intermediate purity factor
concentrates could directly or indirectly cause immunosup-
pression because of the many foreign proteins and alloanti-
gens that they contain.5’6 Thus, a more highly purified
concentrate might be advantageous because it would replace
primarily the missing clotting factor, reducing the infusion of
extraneous plasma proteins and of living or dead viruses. We
report here the results of the use of factor VIII concentrate
purified using affinity chromatography with murine mono-
clonal antibody to human von Willebrand factor (vWF) in
the first seven human patients to receive this material. These
patients all had severe hemophilia A and all had been
exposed to HIV in the past. All seven have been observed for
24 months on this treatment.
Patients
PATIENTS AND METHODS
Seven patients observed at the New England Area Comprehensive
Hemophilia Center who had severe factor VIII deficiency (factor
VIII<1%) were selected. They ranged in age from 16 to 39 years
(median, 26 years). All were HIV antibody positive since 1983, and
all had antibody to hepatitis B surface antigen (HBsAb positive).
patients have infused approximately once per week on the
average, most often for joint hemorrhages. The efficacy of
the concentrate is excellent. No allergic reactions have
occurred and no factor VIII antibodies have developed. In
these seven patients mean CD4 counts stabilized
(856 ± 61 9 at screen v 778 ± 686 at 24 months) and there
was reversal of skin test anergy. In a comparison group on
conventional intermediate purity concentrate chosen
retrospectively decreases in mean CD4 cell counts similarly
did not occur. However, the number of the comparison
patients who were anergic increased over the course of
the study. These observations indicate the possibility that
more highly purified concentrates may stabilize immune
function in HIV seropositive patients.
S 1989 by Grune & Stratton, Inc.
Other selection criteria included: (a) no evidence of AIDS or of
AIDS-related complex; (b) normal platelet count, (c) residence in
proximity to the center to expedite frequent visits, and (d) willing-
ness to sign informed consent. Characteristics of the seven patients
are presented in Table I.
The study participants initially underwent a recovery and half-life
study where approximately 22 to 32 U/kg factor VIII were infused
and blood was drawn after measured intervals as detailed below.
Vital signs including blood pressure, pulse, respiratory rate, and
temperature were monitored. Subsequently two factor concentrate
infusions were administered in the clinic setting, observed, and
monitored by the center staff. After these infusions, the patients used
the concentrate on a home care basis as described previously.3 They
infused on the average of 15 to 25 U/kg/wk with a total dosage
median of 1,454 U/kg/yr (range, 611 to 2,022). One patient was
additionally infused for a minor surgical procedure and the same
patient was infused for trauma secondary to an automobile acci-
dent.
The patients were observed closely with periodic physical exami-
nations and laboratory testing. Laboratory testing included immuno-
logic parameters such as CD4, CD8 cell counts, concanavalin A
lymphocyte stimulation, and delayed cutaneous hypersensitivity as
measured by skin testing as detailed in the next section. These were
performed every 3 to 6 months for 24 months. Additionally, IgE
levels and circulating immune complexes were drawn at screen and 6
months, factor VIII inhibitor titers were obtained every 6 months,
antibody levels to mouse IgG were measured every 4 months, and
half-life and recovery studies were obtained at screen and 6 months.
In order to assess whether changes noted in immune function in
the seven patients during the study were significant, a comparison
group was retrospectively chosen. It consisted ofa matched group of
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Table 1 . Demographic Information
Hemophilia Dose
Patient Type Age (U/k9/yr)
Experimental group
1 ASevere 27 829
2 ASevere 28 611
3 ASevere 26 770
4 ASevere 25 1.559
5 ASevere 22 2.002
6 ASevere 16 2,022
7 ASevere 39 1,454
Comparison group
1C ASevere 28 1,082
2C ASevere 30 782
3C ASevere 23 722
4C ASevere 28 2,071
5C ASevere 24 863
6C ASevere 15 1,359
7C ASevere 33 2.232
seven hemophiliacs on conventional intermediate purity factor VIII
concentrate that was dry heat treated (six patients) or organic
solvent “wet” treated (one patient). This group was matched with
the above patients for HIV serologic status, age, number of CD4
lymphocytes at the start of the study, and annual factor usage. The
median age was 28 (range, 1 5 to 33 years) and median factor usage
was I ,082 U/kg/yr (range, 722 to 3,232). Characteristics of this
comparison group are seen in Table 1.
Methods
Factor VIII concentrate (Monoclate; Armour Pharmaceuticals,
Blue Bell. PA). Cryoprecipitate, the source material, was passed
over an agarose gel column to which a mouse monoclonal antibody to
factor VIIl:vWF (made by Dr T. Zimmerman, Scripps Clinic, La
Jolla, CA) was covalently bound. Factor VIII:C was then eluted
from the column using a calcium chloride gradient, concentrated,
and further purified on a second affinity column. The resultant
concentrate contained 700 to 3,500 units factor VIII:C-mg protein,
which decreased in the final preparation to 5 units of factor
VIII:C/mg protein after albumin was added as a stabilizer. vWF
was present in small quantities and murine monoclonal antibody was
present in minute amounts (from undetectable to 50 ng/mL in the
final product). To enhance viral safety, after the addition of albumin
the concentration was lyophilized and then heat treated to 60#{176}Cfor
30 hours. By Western blot analysis, the factor VIII molecule retains
the same molecular structure as the factor VIII concentrate that is
prepared by the conventional method. There is a >5 log removal of
added HIV with affinity chromatography alone and a >9.1 log
removal of HIV after affinity chromatography plus heat treatment.7
Other model viruses including sindbis virus, vescicular stomatitis
virus, and pseudorabies virus are also significantly reduced during
the purification process and rendered undetectable by heat treat-
ment.7 The concentrate reconstitutes within seconds into a clear
solution.
Factor VIII half-life and recovery. Each patient had a half-life
and recovery study at entry into the protocol. The patient was given
approximately 25 U/kg of factor VIII concentrate. Blood was drawn
at 30 minutes and at 1, 2, 4, 6, 8, 24, and 48 hours after the infusion;
factor VIII levels were determined at each time point. Using linear
least squares, a linear equation was estimated for the terminal phase
of the factor VIII activity level against time curve. In vivo half-life
(t’/) was then estimated from the formula t’/ = .693/B, where B =
slope of factor VIII activity v time profile. Recovery (K) in units per
deciliter was calculated by the following formula: K = body weight
(kg) x factor VIII rise (U/dL)/dose of factor VIII concentrate
administered (u). Half-lives and recovery data were also obtained at
6 months, as a sensitive measure of possible development of low level
inhibitor antibody. Inhibitor assays were carried out at screen, and at
6, 1 2, and 24 months, using the Bethesda method of Kasper et al.8
Immunologic testing. Peripheral blood mononuclear cells
(PBMC) were isolated from freshly drawn heparinized venous blood
by centrifugation on Ficoll-Hypaque (Pharmacia Fine Chemicals,
Inc. Piscataway, NJ) density gradients. Relative percentages of
T-lymphocyte populations were enumerated using indirect immuno-
fluorescence and the following mouse monoclonal antibodies:
OKT1 1, OKT4, and OKT8 (Ortho Pharmaceutical Co, Raritan,
NJ). All samples were analyzed using a Becton-Dickenson FACS IV
fluorescence activited cell sorter. Absolute numbers of various cell
populations per microliter of whole blood were calculated by mul-
tiplying their relative percentage by absolute numbers of mononu-
clear cells as determined from complete blood counts.
Delayed cutaneous hypersensitivity. The Multitest skin test
antigen set (Multitest CMI; Merieux Institute, Inc. Miami, FL) was
used on each patient, as reported previously.9 The seven antigens
included tetanus toxin, candida, proteus, tuberculin, diptheria tox-
oid, streptococcus, trichophyton, and a glycerol control. The test was
applied to the volar service of the forearm and read at 48 hours by
the patient using a guide provided by the center after a teaching
program. A response was considered positive if the induration
measured 2 mm or greater. A patient was considered anergic if he
did not respond to any of the seven test antigens. A patient was
considered nonanergic if he responded to one or more test antigens.
Measurement ofhuman anti-murine IgG. Human anti-murine
IgG was measured by an ELISA technique.7 Flexible 96 well
polvinylchloride plates (Dynatech) containing 50 zL/well of murine
monoclonal antibody used during the factor VllI:C purification
process or a human IgG standard suspended in PBS were incubated
at 37#{176}C.The plates were then aspirated and washed, after which 50
L of patient serum or control were placed in the wells, incubated for
four hours, at 4#{176}C,and washed three times with PBS buffer. Fifty
microliters 251 goat anti-human IgG was placed in each well; the
plates were incubated for I 5 hours at 4#{176}C.washed three times with
buffer, and the individual wells counted in a gamma counter.
Absolute counts per minute (cpm) values were computed into bound
over total input cpm percentages. A standard curve was constructed
from the microtiter wells coated with 50 zL human IgG ranging in
concentration from 0.5 to 20 jg/mL.
Other testing. Other testing included response of lymphocytes to
the lectin concanavalin A (Con A), circulating immune complexes,
and IgE levels. Response to Con A was measured using a standard
microculture technique’#{176}where 5 x IO PBMC in 0.25 mL of RPMI
1640 (Grand Island Biological Co. Grand Island, NY) supple-
mented with 10% fetal calfserum (Grand Island Biological Co) were
distributed into replicate wells of Microtiter II plates (Falco Lab-
ware, Oxnard, CA). Con A (Calbiochem-Boerhing Corp. San Die-
go) was added in concentrations of 0.4 to 40 g/mL and the plates
cultured for five days at 37#{176}Cin a 5% CO2 environment. Eighteen
hours before harvesting, the cells were pulsed with 3H thymidine,
(specific activity, 6.7 Ci/mmol; New England Nuclear, Boston).
Cells were harvested onto glass fiber filters and 3H thymidine
content was determined by scintillation counting. All cultures were
performed in triplicate. Results are reported as maximum cpm.
Circulating immune complexes were measured at screen and at 6
months using the Raji method.” Normal values range between 0 and
50 .tg aggregated human gammaglobulin (AHG) equivalents per
milliliter. IgE levels were determined using a simultaneous sandwich
technique (Kallestad, Austin, TX). Briefly, to a 20 L serum
sample, a mixture of ‘251-radiolabeled equine anti-human IgE and
cold mouse anti-human lgE were added and incubated. Goat
anti-mouse IgG was then added, the mixture incubated, and the tube
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Fig i . Representative factor VIII half-life at screen (first dose)
and at 6 months (second dose).
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centrifuged to separate the bound radiolabeled antibody-IgE com-
plexes that precipitated. The supernatant was decanted and the
precipitate counted to measure the bound radioactivity. The amount
of radioactivity was proportional to the concentration of IgE in the
sample as determined by a calibration curve. Results were consid-
ered normal in the range of 0 to 180 IU/mL.
p24 Antigen. Serum samples were analyzed for p24 antigen
using the Abbott HTLV III Antigen EIA Kit (#4234-22 Abbott
Diagnostics, Chicago). Briefly the assay is a “sandwich” solid phase
enzyme immunoassay. The sample is considered positive or negative
for HIV antigen(s) by comparing the absorbance at 492 nm of the
specimen to a cutoff value. The cutoff value is the absorbance of the
mean of the negative control plus the factor of 0.050. Samples with
absorbance values greater than or equal to the cutoff value are
considered reactive for HIV antigen(s).
Statistical analysis. The Paired Student’s t test was used to
compare the means of lymphocyte cell counts at screen and 24
months of the group on experimental factor or conventional factor
and also to compare the means of the group on experimental factor
concentrate v conventional factor concentrate at the 24-month
period.
Safety and Efficacy
RESULTS
The median amount of factor concentrate used by each
patient during the study is shown in Table 1 . Infusions were
given for joint and soft tissue hemorrhages, and in one case
for arthroscopy. Hemostatic efficacy was judged excellent by
all patients for all episodes. When the seven patients were
infused under physician supervision, there were no changes
in vital signs. No side effects of the factor were noted during
the study. Recovery was excellent and was not significantly
different when determined at screen and at 6 months into the
study. At screen the recovery value was I .9 ± 0.3 U/dL/kg
and at 6 months it was 2.2 ± 0.4 U/dL/kg; the anticipated
recovery for factor VIII is 2.0 U/dL/kg. The half-life was
also comparable with conventional concentrates of I 5.4
hours ± 2.2 at screen and 17.5 hours ± 5.9 at 6 months
(expected, 8 to I 2 hours). The half-life and recovery data are
seen in Table 2. A representative t’/2 curve is seen in Fig 1.
Immunologic Results
As seen in Table 3, at screen the mean CD4 cell level was
856 ± 619 cells/zL and at 24 months it was 778 ± 686
cells/zL, which was not a significant change. The total
amount of T cells was I ,206 ± 529 cells/zL at screen and
I ,789 ± 1 ,888 cells/L at 24 months; helper/suppressor cell
ratios decreased slightly but not significantly over the 24
months of the trial (from 1.11 ± 0.34 to 0.91 ± 0.52). Skin
test anergy decreased in the group on experimental factor as
seen in Table 4. The number of patients that were anergic at
the onset of the study (three of seven) decreased to one of
seven at the 24 month point. At screen, the mean number of
skin test antigens to which the group responded was 1 .6 ±
1 .6. At 24 months, the mean number of skin test antigens to
which the patients responded was to 2.9 ± I .7 antigens, a
nonsignificant difference.
When immunologic function was compared over 24
months to the subset of seven matched patients that were on
conventional concentrate, it was found that the group on
conventional concentrate also did not have a significant
decrease in mean CD4 cell level (684 ± 282 cells/zL v
Table 2. Half-Life and Recovery of Monoclonally
Purified Factor VIII
Patient
Weight
(kg)
Dose
(U)
Maximum FVIII
Level
Halt-Life
(hr) Recovery
Screen/baseline
1 74.6 2,135 48 15.4 1.7
2 83.2 2,562 63 13.7 2.0
3 70.5 2,135 49 13.4 1.6
4 110.0 3,416 64 12.6 2.1
5 65.9 2.135 52 18.4 1.6
6 60.9 1.640 47 17.5 1.7
7 65.5 1,640 61 16.6 2.3
Mean 15.4 1.9
SD 2.2 0.27
Six months
1 75.4 1,840 55 14.4 2.3
2 82.7 2,080 72 11.0 2.9
3 70.9 1,840 53 16.3 2.0
4 113.6 2,800 50 14.4 1.9
5 72.3 1,600 45 29.1 2.0
6 60.4 1,440 48 20.5 2.0
7 65.5 1,710 64 16.6 2.4
Mean 17.5 2.2
SD 5.9 0.35
603 ± 403, P = NS) over 2 years, (Table 5). However, while
only one subject in the experimental group (patient no. 7)
dropped his CD4 count by 50% or more, three of the
comparison subjects (patients 4C, 6C, and 7C) had declines
of this magnitude. One patient on conventional concentrate
was anergic at the outset, as compared with three patients on
the experimental concentrate. After 24 months two of six
patients on conventional concentrate were anergic as com-
pared with one of seven patients on the experimental factor.
Clinically, no patient on the experimental factor has
developed AIDS while two patients on the conventional
intermediate purity concentrate (6C, 7C) have become ill
with AIDS. Of interest also is that of six of seven patients
tested for p24 antigen in the experimental group one was
positive (patient no. 7), while no patient of six tested in the
comparison group was positive (data not shown). Patient no.
7, even with decreases in CD4 cell count and a positive p24
Ag remains asymptomatic. Additionally, liver function tests
80
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Table 4. Number of Skin Test Antigens to Which Each Patient on Experimental Concentrate Responded
Patient
Months
Screen 3 6 14 18 24
1
2
3
4
5
6
7
Mean ± SD
0 0
0 ND
3 2
2 5
4 4
0 1
2 3
1.6 ± 1.6 2.5 ± 1.9
2
2
3
3
6
4
0
2.9 ± 1.9
1
5
3
3
5
ND
4
3.5 ± 1.5
2
4
3
NE
3
2
2
2.7 ± 0.8
4
4
4
3
4
1
0
2.9 ± 1.7
Abbreviations: ND. not done; NE, not evaluable.
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Table 3. Quantitative CD4 C elI Subsets (Cells /L) in Patien ts on Experimental Concentrate
Patient Screen
Months
3 6 10 14 18 24
1
2
3
4
5
6
7
Mean ± SD
627
1,219
899
2,058
535
356
297
856 ± 619
991
707
677
1.980
167
ND
288
802 ± 651
660
943
561
2.125
607
576
195
810 ± 620
864
868
810
2,116
482
392
ND
922 ± 620
727
777
813
1,930
494
369
145
750 ± 573
485
620
813
1,500
920
469
131
705 ± 434
581
1,280
707
2.071
358
414
38
778 ± 686
were not significantly different between the experimental
group and comparison group at the outset of the study and
this did not change during the 2-year course of study (data
not shown).
Additional Immune Studies
The results of con A stimulation showed no significant
change in the experimental group between screen values
(48,146 ± 24,646 cpm) and values at 18 months
(32,83 1 ± I 6,554 cpm). Levels of circulating anti-mouse
antibody were in the lower limits of the assay (5 to 7.8
g/mL) before the start of the study for six of seven patients.
One patient had an elevated screen level of 13.8 zg/mL due
to the presence of rheumatoid factor, which interfered with
the ELISA assay. No increase in levels was seen over 6
months of the study except for the patient with the rheuma-
toid factor whose level rose to 25.2 tg/mL. Mean IgE level
was 1 3 1 . I ± 91 . 1 IU/mL (normal range, 0 to I 80) at screen
and at 6 months mean levels were I 1 5.9 ± 88.3. Mean
circulating immune complexes were elevated at screen
(360 ± 73 ig AHG eq/mL; range, 243 to 462) and did not
change significantly when tested at 6 months (366 ± 167;
range, 246 to 718). Subsequent testing for IgE, circulating
immune complexes, and anti-mouse IgG was not repeated.
No patient developed an inhibitor to factor VIII over the
course of the study.
DISCUSSION
Factor concentrate purified using affinity chromatogra-
phy and a monoclonal antibody to factor VIII:vWF has been
shown by this study to be safe and efficacious over a
prolonged period of time. It has been demonstrated by others
that activating latently HIV infected mononuclear cells with
mitogens may lead to HIV replication.’2 More recently it has
been demonstrated that latently infected cells may also be
stimulated to express HIV when stimulated by other viruses
such as CMV and hepatitis B.’3”4 Because >80% of patients
with severe hemophilia over the age of 5 years are positive for
HIV antibody and thus presumably latently infected with
HIV, the theoretic advantage of purer factor VIII concen-
trate product may be less expression of HIV in an infected
patient over a period of time.
In the seven patients studied, stabilization of CD4 cell
levels seemed to occur, as well as an improvement in delayed
cell mediated immunity as determined by decrease in the
number of patients who demonstrated skin test anergy.
However, in the comparison group, matched for HIV sero-
positivity, CD4 level, age, and factor usage, there was also no
significant decrease in mean CD4 levels over 2 years. The
number of patients that were anergic at the outset decreased
over 2 years in the group using experimental concentrate,
while the number of patients that were anergic increased in
the group on conventional concentrate. Within each group,
however, the mean number of individual antigens to which
the patients responded to did not change. The numbers of
positive responses also was not significantly different
between the two groups at the end of 24 months. Two
patients have developed AIDS in the group using conven-
tional intermediate purity concentrate while all patients
remain asymptomatic on the experimental factor. The num-
ber of patients, however, is very small. Additionally, the
comparison group was chosen retrospectively. Thus, defini-
tive conclusions about effects of the experimental concen-
trate on immune system stabilization or improvement cannot
be drawn.
It is interesting to note that in in vitro experiments looking
at the effect of factor concentrates on human mixed lympho-
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Table 5. Results of 1mm une Studies in Compariso n Group
Patient
CD4
(ceIIs4tL)
CD4
(cells/zL)t
SkinTest
(No. of
Antigens
Positive)
Skin Testt
(No. of
Antigens
Positive)
1C 743 874 ND 2
2C 1,037 692 2 4
3C 760 895 2 2
4C 996 445 0 ND
SC 563 882 1 2
6C 297 22 0 0
7C 397 132 1 0
Mean ± SD 684 ± 282 603 ± 403 1.8 ± 1.5 1.7 ± 1.9
Abbreviation: ND, not done.
‘Represents values at screen.
tRepresents values at 2 years.
cyte reactions and phytohemagglutinin mitogenesis, conven-
tional concentrates induced 50% inhibition at approximately
I mg/mL protein concentration, while the experimental
concentrate induced no inhibition at any concentration
examined.’5 Additionally, intermediate purity concentrates
have been shown to downregulate Fc receptors on mono-
cytes.’6 This data may have clinical relevance in determining
if “purer” factor VIII concentrate may improve or stabilize
deteriorating immune function.
Whether HIV and non-A, non-B hepatitis virus are com-
pletely eliminated by this new manufacturing process cannot
be assessed by this study since all the patients studied were
HIV antibody positive at the outset and also had presumed
non-A, non-B hepatitis secondary to previous long-term
exposure to conventional concentrates. This issue is currently
being addressed in a study involving approximately 40
hemophilic patients who had been previously untransfused
and now have been using only the highly purified concen-
trate. Additionally, now that adequate supplies of this new
blood derivative are available, a randomized controlled study
of a large number of patients is ongoing in order to attempt to
determine conclusively whether purer factor concentrates
are of benefit for persons with hemophilia who have previ-
ously been infected with HIV. Only when such randomized
trials are completed can the issue of cost/benefit of these new
more expensive concentrates be adequately answered.
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